Statin-mediated low-density lipoprotein lowering in chronic congestive heart failure

American Journal of the Medical Sciences

Volumn 347, Issue 1, 2014, Pages 14-22

  Kosmas, Constantine E ^a   Alkhawam, Hassan ^b,c   El Hunjul, Mohammed ^b,c   Wagman, Gabriel ^d,e   Kahn, Mark R ^b,f   Grady, Kathleen M ^g   Vittorio, Timothy J ^d,e  

^a Zena and Michael A Wiener Cardiovascular Institute   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Faculty of Pharmacy   (United States)

^d CAIRO UNIVERSITY   (Egypt)

^e ST FRANCIS HOSPITAL   (United States)

^f Center of Advanced Cardiac Therapeutics   (United States)

^g Cardiovascular Consultants of Long Island   (United States)

Author keywords

Cholesterol; Coenzyme Q10; Cytokine; Endotoxin; Heart failure; Statins.

Indexed keywords

ENDOTOXIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; UBIDECARENONE;

ARTICLE; CHRONIC DISEASE; CONGESTIVE HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; AGED, 80 AND OVER; CHRONIC DISEASE; ENDOTOXINS; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME; UBIQUINONE;

EID: 84891837186     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318273514c     Document Type: Article

References (77)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012;125:e2-e220.
2. Cholesterol and Recurrent Events Trial Investigators; Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
3. West of Scotland Coronary Prevention Study Group; Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333: 1301-7.
4. Fonarow GC. Randomized clinical outcome trials of statins in heart failure. Heart Fail Clin 2008;4:225-9. This study reviews the randomized clinical trials of statins in heart failure with special focus on CORONA.
5. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
6. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41.
7. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-a and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704-11.
8. Habib FM, Springall DR, Davies GJ, et al. Tumor necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996; 347:1151-5.
9. Seta Y, Shan K, Bozkurt B, et al. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 1996;2:243-9.
10. Tarantino G, Saldalamacchia G, Conca P, et al. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol 2007;22:293-303.
11. Tarantino G, Finelli C, Colao A, et al. Are hepatic steatosis and carotid intima media thickness associated in obese patients with normal or slightly elevated gamma-glutamyl-transferase? J Transl Med 2012; 10:50.
12. Tarantino G, Caputi A. JNKs, insulin resistance and inflammation: a possible link between NAFLD and coronary artery disease. World J Gastroenterol 2011;17:3785-94.
13. Tarantino G, Savastano S, Colao A. Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. World J Gastroenterol 2010;16:4773-83.
14. Tarantino G, Colicchio P, Conca P, et al. Young adult obese subjects with and without insulin resistance: what is the role of chronic inflammation and how to weigh it non-invasively? J Inflamm (Lond) 2009;6:6.
15. Tarantino G, Conca P, Basile V, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007;37:410-5.
16. Tarantino G, Di Minno MN, Capone D. Drug-induced liver injury: is it somehow foreseeable? World J Gastroenterol 2009;15:2817-33.
17. Elliot DC, Wiles CE III. Low lipid concentration in critical illness; hypocholesterolemia among trauma patients. Crit Care Med 1994;22: 1437-9.
18. Gui D, Spada PL, De Gaetano A, et al. Hypocholesterolemia and risk of death in the critically ill surgical patient. Intensive Care Med 1996; 22:790-4.
19. Fraunberger P, Nagel D, Walli AK, et al. Serum cholesterol and mortality in patients with multiple organ failure. Crit Care Med 2000; 28:3574-5.
20. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458-82.
21. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000;356:930-3.
22. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-7.
23. Popa C, Netea MG, van Riel PL, et al. The role of TNF-a in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 2007;48:751-62.
24. Rosenson RS, Elliott M, Stasiv Y, et al. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. Eur Heart J 2011;32:999-1005.
25. Anker SD, Egerer K, Volk HD, et al. Elevated soluble CD 14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997; 79:1426-30.
26. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999; 353:1838-42.
27. Torre-Amione G, Kapadia S, Benedict CR, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies on Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-6.
28. Vanderheyden M, Kersschot E, Paulus WJ. Pro-inflammatory cytokines and endothelium-dependent vasodilation in the forearm: serial assessment in patients with congestive heart failure. Eur Heart J 1998; 19:747-52.
29. Munger MA, Johnson B, Amber IJ, et al. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996;77:723-7.
30. Crane FL, Hatefi Y, Lester RL, et al. Isolation of a quinone from beef heart mitochondria. Biochim Biophys Acta 1957;25:220-1.
31. Mellors A, Tappel AL. Quinone and quinols as inhibitors of lipid peroxidation, Lipids 1996;1:282-4.
32. Schmelzer C, Niklowitz P, Okun JG, et al. Ubiquinol-induced gene expression signatures are translated into altered parameters of erythropoiesis and reduced low density lipoprotein cholesterol levels in humans. IUBMB Life 2011;63:42-8.
33. Littarru GP, Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol 2007;37:31-7.
34. Kato T, Yoneda S. Reduction in blood viscosity by treatment with coenzyme Q10 in patients with ischemic heart disease. Int J Clin Pharmacol Ther Toxicol 1990;28:123-6.
35. Folkers K, Vadhanavikit S, Mortensen SA, et al. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci USA 1985;82: 901-4.
36. Crane FL. Biochemical functions of coenzyme Q10, J Am Coll Nutr 2001;20:591-8.
37. Sander S, Coleman CI, Patel AA, et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail 2006;12:464-72.
38. Molyneux SL, Florkowski CM, George PM, et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure J Am Coll Cardiol 2008;52:1435-41.
39. Baggio E, Gandini R, Plancher AC, et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. Mol Aspects Med 1994;15:S287-94.
40. Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure J Am Coll Cardiol 1999;33:1549-52.
41. Khatta M, Alexander CM, Fisher ML, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med 2000;132: 636-40.
42. Keogh A, Fenton S, Leslie B, et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart Lung Circ 2003;12:135-41.
43. Hosseini VN. Comparison of coenzyme Q10 versus placebo in chronic heart failure. Res J Biol Sci 2008;3:546-9.
44. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61.
45. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372: 1223-30.
46. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebocontrolled trial. Lancet 2008;372:1231-9.
47. Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003;42:1933-40.
48. Kjekshus TR, Pedersen AG, Olsson O, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997;3:249-54.
49. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004;43:642-8.
50. Node K, Fujita M, Kitakaze M, et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003;108: 839-43.
51. de Lorgeril M, Salen P, Bontemps L, et al. Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients. J Cardiovasc Pharmacol 1999;33:473-8.
52. Foody JM, Shah R, Galusha D, et al. Statins and mortality among elderly patients hospitalized with heart failure. Circulation 2006;113: 1086-92.
53. Hognestad A, Dickstein K, Myhre E, et al; OPTIMAAL Investigators. Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. Am J Cardiol 2004;93: 603-6.
54. Segal R, Pitt B, Poole-Wilson P, et al. Effects of HMG-CoA reductase inhibitors (statins) in patients with heart failure (abstr). Eur J Heart Fail 2000;2(suppl 2):96.
55. Ramasubbu K, Estep J, White DL, et al. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008;51:415-26.
56. Ray JG, Gong Y, Sykora K, et al. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 2005; 165:62-7.
57. Hayashidani S, Tsutsui H, Shiomi T. Fluvastatin, a 3-hydroxy-3 methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002;105:868-73.
58. Bauersachs J, Galuppo P, Fraccarollo D, et al. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001;104:982-5.
59. Luo JD, Zhang WW, Zhang GP, et al. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol 1999;26:903-8.
60. Oi S, Haneda T, Osaki J, et al. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol 1999;376:139-48.
61. Dechend R, Fiebeler A, Park JK, et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation 2001;104:576-81.
62. Hamilton PK, Hughes SM, Plumb RD, et al. Statins have beneficial effects on platelet free radical activity and intracellular distribution of GTPases in hyperlipidaemia. Clin Sci (Lond) 2010; 118:359-66.
63. Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: 1383-9.
64. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-57.
65. McMurray JJ, Dunselman P, Wedel H, et al. Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (Controlled Rosuvastatin Multinational Study in Heart Failure). J Am Coll Cardiol 2010;56:1196-204.
66. Choi CU, Seo HS, Lee EM, et al. Statins do not decrease small, dense low-density lipoprotein. Tex Heart Inst J 2010;37:421-8.
67. Maki KC, Bays HE, Dicklin MR, et al. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoproteinassociated phospholipase A2 mass in men and women with mixed dyslipidemia. J Clin Lipidol 2011;5:483-92.
68. Cleland JG, Massie BM, Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Fail 1999;1:41-5.
69. Cleland JG, McMurray JJ, Kjekshus J, et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin. J Am Coll Cardiol 2009;54:1850-9.
70. Chin JP, Gust AP, Nestel PJ, et al. Marine oils dose-dependently inhibit vasoconstriction of forearm resistance vessels in humans. Hypertension 1993;21:22-8.
71. Li Q, Zhang Q, Wang M, et al. Docosahexaenoic acid affects endothelial nitric oxide synthase in caveolae. Arch Biochem Biophys 2007; 466:250-9.
72. Grimsgaard KH, Bønaa JB, Hansen D, et al. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans. Am J Clin Nutr 1998;68:52-9.
73. Mozaffarian D, Geelen A, Brouwer IA, et al. Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation 2005;112:1945-52.
74. Mozaffarian D, Bryson CL, Lemaitre RN, et al. Fish intake and risk of incident heart failure. J Am Coll Cardiol 2005;45:2015-21.
75. Mozaffarian D, Stein PK, Prineas RJ, et al. Dietary fish and n-3 fatty acid consumption and heart rate variability in US adults. Circulation 2008;117:1130-7.
76. Pepe S, McLennan PL. Cardiac membrane fatty acids composition modulates myocardial oxygen consumption and postischemic recovery of contractile function. Circulation 2002;105:2303-8.
77. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSIPrevenzione trial. Lancet 1999;354:447-55.